Introduction
Staphylococcus aureus, a gram-positive bacterium, can reside in the human body both as a commensal or as an opportunistic pathogen and accounts for the majority of the deaths and hospitalization globally. Staphylococcal infections caused by methicillin-sensitive S. aureus can easily be cured with penicillins or cephalosporins (1) . Resistance to methicillin (defined as minimum inhibitory concentration (MIC) of oxacillin ≥ 4 µg/ mL) (2) , mediated mainly by the mecA gene, was observed shortly after the introduction of methicillin (3) . Since then, methicillin-resistant S. aureus (MRSA) developed itself as a leading cause of death and major clinical threat with more than 60% S. aureus isolates becoming resistant to methicillin (4) . Vancomycin, a glycopeptide antibiotic produced by Amycolatopsis orientalis, has been the mainstay of treatment against infections caused by methicillin-resistant S. aureus (1) . In 1996, S. aureus with reduced susceptibility to vancomycin (MIC 8 µg/mL), referred as vancomycinintermediate S. aureus (VISA), was isolated in Japan (5) . The first case of vancomycin-resistant S. aureus (VRSA) was first isolated in 2002 in the USA and following it, at least 14 cases of VRSA have been identified in the United States, and the first case in Europe was reported in 2013 (6) . vanA type vancomycin resistance is the most prevalent vancomycin resistance and has been associated with the synthesis of an alternative, vancomycin-resistant pentatdepsipeptide peptidoglycan precursor (7) . Genomic analysis of the strains resistant to vancomycin is critical to understand the genetic background and identify the difference between the strains, thus facilitating the development of novel anti-VRSA drugs.
S. aureus VRS3b was co-isolated with S. aureus VRS3a from nephrostomy tube exit site of a 64-year old female in New York, USA. As these two strains were isolated from the same patient, they were considered to be identical, and the characterization has been performed mainly for VRS3a. However, the vancomycin-resistant phenotype of VRS3b is more stable than VRS3a (8 multiple VRSA strains has been sequenced (9) and the study excluded the strain VRS3b considering it to be same as the strain VRS3a. In this study, we sequenced and analyzed the draft genome of VRS3b strain to reveal the genetic basis of drug resistance and its difference with the strain VRS3a.
Materials and Methods

Draft genome sequences of VRSAs
Strain VRS3a and VRS3b were obtained from BEI Resources and grown at 37°C aerobically in tryptic soy broth containing 6 µg/mL vancomycin. Genomic DNA was isolated using Qiagen DNA-blood Mini Kit (Qiagen, Hilden, Germany) (10, 11) . One hundred ng of the DNA was subjected to fragmentation using Ion Xpress Plus Fragment Library Kit (Thermo Fisher Scientific, Waltham, MA, USA) to prepare 400 bp reads according to manufacturer's recommended protocol. The libraries were then enriched in an Ion Chef (Thermo Fisher Scientific) and subsequent sequencing was performed in Ion PGM System (Thermo Fisher Scientific). The reads were first assembled in the Ion Torrent Server (Thermo Fisher Scientific) and then analyzed in the CLC Genomics Workbench ver 9.5.3.
(CLC bio, Aarhus, Denmark). The draft sequences were downloaded from NCBI using following GenBank accession numbers AHBK00000000 -VRS1; AHBL00000000 -VRS2; AHBM00000000 -VRS3a; NBCP00000000 -VRS3b; AHBN00000000 -VRS4; AHBO00000000 -VRS5; AHBP00000000 -VRS6; AHBQ00000000 -VRS7; AHBR00000000 -VRS8; AHBS00000000 -VRS9; AHBT00000000 -VRS10; AHBU00000000 -VRS11a; AHBV00000000 -VRS11b; and JICL00000000 -BR-VRSA.
Genomic analysis of VRSAs
Sequencing typing
The draft genomes (9, 11) 
Analysis of resistance genes
The recent database to find resistance was downloaded from the server (12) . The database consisted of 2,156 genes known to be involved in the resistance against multiple antibiotics. The presence of resistance gene on the draft genome was scanned with a minimum identity 
Determination of minimum inhibitory concentration
The MIC was determined by broth microdilution assay (13) (14) (15) . Briefly, Staphylococci were grown with aeration in 50-mL falcon tube containing 5 mL Tryptic Soy Broth (TSB; Becton Dickinson and Company, Franklin Lakes NJ, USA) in a shaker maintained at 37°C. The medium was supplemented with 6 µg/mL vancomycin as required. The overnight culture was diluted with cation-adjusted Muller-Hinton Broth (MHB; Becton Dickinson and Company) to have approximately 5 × 10 4 colony forming units (CFU) per 100 µL in each well in a round bottom 96-well plate. Serial dilutions of antibiotics were added to each well to obtain a final concentration of 128 µg/mL to 0.0125 µg/ mL. The plates were further incubated at 37°C for 20 h and MIC was determined as the lowest concentration that did not allow visible growth of cell.
Results
The phylogeny of VRSAs
We found that the 14 VRSAs were categorized among five sequence types (STs): ST5, ST8, ST85, ST231, and ST371. ST5 was the most predominant group with eight VRSAs falling within this group (Figure 1a) . The strain VRS4 could not be typed as the arcC locus in this strain had a deletion of a nucleotide and the trimmed length was different from the standard length. Previous reports have characterized the strain VRS4 as ST5 (9) . Further, we constructed a phylogenetic tree based on the sequences used for sequence typing and found that VRS4 clustered with other VRSAs of ST5 group. The strain BR-VRSA was categorized to be ST8, same as the methicillin-resistant, vancomycin-sensitive strain USA300 strain and based on the phylogenetic tree, it also claded with the USA300 rather than other VRSAs (Figure 1b) .
Presence of antibiotic resistance genes in VRSAs
When checked for the presence of antibiotic resistance genes, we found that all the strains of VRSAs harbored mecA gene, involved in resistance to methicillin. Further, multiple genes involved in the resistance against clinically used antibiotics such as vancomycin, aminoglycosides, streptogramins and macrolides were identified in the draft genome (Table 1 ). This finding, in fact, indicated the complexity of VRSA treatment in the clinic. Interestingly, the drug resistance genes were not the same among these strains. This difference might reflect the clinical setting where most of the patients from whom these VRSAs were isolated had a history of several underlying conditions and were exposed to multiple antibiotics during isolation. Among the VRSAs, VRS3a and VRS3b were considered to be same as these two strains were isolated from the same patient source. Our analysis indicated that antibiotic resistance genes were not the same among these two strains.
Comparative analysis of strains VRS3a and VRS3b
We found that VRS3b did not harbor the putative genes that conferred resistance to tetracycline and aminoglycosides such as kanamycin and gentamicin. To confirm this, we determined the MIC of these two strains and found that VRS3a was resistant to these antibiotics whereas VRS3b was sensitive to tetracycline and gentamicin but resistant to kanamycin (Table 2 ). Resistance to kanamycin but not to gentamicin in S. aureus might be ascribed to aph(3')-III gene (16) . Given that the sequence we generated was a draft genome, we performed a blast search for this gene in all contigs generated from the VRS3b sequence. We found a part of aph (3' )-III at the terminal position of a contig less than 1,000 bp suggesting that this might be responsible for resistance to kanamycin but not gentamicin in VRS3b. These results further suggested that these two strains were different. To confirm this notion, we mapped the reads obtained from de novo sequencing of VRS3a against the VRS3b contigs. We found that some of the genes present in VRS3b were missing from the VRS3a reads (Table 3) .
Comparative analysis of Tn1546
Transposon Tn1546, obtained from vancomycinresistant Enterococcus (17) , has been shown to be one of the responsible elements of vancomycin resistance in VRSAs (7) . The analysis of the genome indicated that all the VRSAs but VRS3a, VRS3b, and BR-VRSA harbored complete sets of genes from Tn1546. To further confirm this result, we independently mapped the reads from strains VRS3a and VRS3b and found that these strains did not harbor transposase and part of resolvase from Tn1546 (Figure 2 ).
Discussion
The clinical isolates of MRSA with decreased susceptibility to vancomycin (VISA) and high-level vancomycin resistance (VRSA) pose a serious threat to public health. Comparative genomic analysis of the clinical isolates of VRSA will facilitate our understanding of how these strains acquired the antibiotic resistance gene. Successful growth of these isolates in mixed culture and their ability to overcome the continuous antibiotic selection pressure in the hospital further highlights the importance of this issue. Here, we showed that the genes conferring resistance to methicillin, vancomycin and erythromycin were common in all the VRSAs and the genes conferring resistance to other antibiotics such as beta lactams, macrolide and tetracycline were distributed. Besides, we found that the strain VRS3b was typically different from VRS3a. Furthermore, we demonstrated that some of the genes present in VRS3b were missing in VRS3a. Although we could not precisely predict whether these two strains independently acquired vancomycinresistance trait or diverged after the acquisition of the vancomycin resistance, our results suggested that these two strains acquired vancomycin-resistance in a similar manner. Our findings highlighted the possibility of generation of two different VRSA strains from the same source.
